Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.
The pharmaceutical company on Thursday posted net income of $1.46 billion, or $1.60 a share, compared with $4.24 billion, or $4.31 a share, in the comparable quarter last year. Lilly said it booked a $3.68 billion gain related to the disposition of Elanco last year.
Adjusted earnings were $1.75 a share, beating the $1.48 a share analysts polled by FactSet had expected.
|LLY||ELI LILLY & CO.||243.50||-1.83||-0.75%|
Sales rose 15% to $5.86 billion, ahead of the $5.49 billion analysts had expected. The company said it had strong demand for key products such as Trulicity, Taltz and Emgality as well as an additional $250 million due to buying patterns and prescription trends amid the pandemic.
U.S. sales rose 15% to $3.33 billion, and revenue outside the U.S. grew 15% to $2.53 billion.
The company has said it was delaying most new study starts and pause enrollment in most ongoing study starts, in an effort to ease the burden on health-care facilities and allow physicians to focus on dealing with the pandemic.
Lilly earlier this month said it is testing baricitinib, a rheumatoid arthritis drug, for patients hospitalized with Covid-19.